Modality Solutions announced hiring pharmaceutical veteran Judy Tempel as a principal consulting engineer. She will work on cold-chain technical support, storage, distribution, and accountability for clinical trials.
Tempel is currently responsible for clinical operations for vaccines for infectious diseases in challenging emerging markets.
ISPE, the International Society for Pharmaceutical Engineering, reports that it is surveying patients globally on their experiences with clinical trial materials. The goal is to gather feedback on the suitability of clinical trial packaging, label information and design, interacting with clinical trial technologies, and transportation and storage, ISPE reports in a press release. With a target of 2000 or more patients from around the world, this study is the first known of its kind in size and scope, it reports.
ISPE (www.ispe.org) has developed industry guidance to help companies conducting global clinical trials standardize booklet labels. Available for purchase on the group’s Web site (http://www.ispe.org/ispe-good-practice-guides/booklet-labels), the ISPE Good Practice Guide: Booklet Labels was developed to help train clinical trial personnel on proper booklet label use.
Immunotech Laboratories, Inc. today announced the company has been in negotiations with an International Bio-Tech Partner in the HIV cure technology sector for joint advanced Research & Development and the partner has agreed to provide the necessary funding for the USA Clinical Trials phases to ultimately achieve FDA approval for the medicines.
Eli Lilly and Co. today announced data from a Phase III trial comparing the effects of FORTEO (teriparatide [rDNA origin] injection) and risedronate on back pain in postmenopausal women with osteoporotic vertebral fractures.
Ventus Medical announces the publication of clinical trial data for its new Theravent Advanced Nightly Snore Therapy in Sleep Diagnosis and Therapy, a medical journal for sleep professionals.
Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced the publication of preclinical research with ADXS-PSA (ADXS31-142), Advaxis’ Lm-LLO immunotherapy targeting the PSA antigen associated with prostate cancer.